Category: Intellectual Proprety

The MENA Community Advisory Board (MENA-CAB) 2017 Report

The Community Advisory Board (CAB) constitutes a space of exchange between advocates from the MENA region,  researchers and drug manufacturers, with the aim to educate people living with HIV and their advocates on access to treatment, to disseminate information about...

/ 14 September 2018

Call for application : MENA-CAB meeting 2018

Are you advocates of the right to health and access to treatment? or activist living with HIV, hepatitis C, hepatitis B or tuberculosis in the North Africa and Middle East (MENA) region? Would you like to participate in an interactive...

/ 12 September 2018

GSIPA2M streaming

PATHWAYS TO ACCESS 15-17 January 2018 MARRAKESH – MOROCCO Read More

/ 15 January 2018

GLOBAL SUMMIT ON INTELLECTUAL PROPERTY & ACCESS TO MEDICINES:

PATHWAYS TO ACCESS 15-17 January 2018 MARRAKESH - MOROCCO

/ 7 January 2018

New Study : Assessment of national intellectual property landscapes and their impact on access to medicines (Egypt, Morocco, Tunisia)

Title: A tool to assess how friendly to access-to-medicines your law is Background Provisions of intellectual property (IP) may have an important impact on access to medicines. For instance, the monopoly granted by the patent prevents competition with generics on...

/ 26 October 2017

ITPC-MENA organize its Middle East and North Africa Community Advisory board (MENACAB)

The International Treatment Preparedness Coalition in Middle East and North Africa (ITPC-MENA) is organizing its Middle East and North Africa Community Advisory board (MENACAB), in late November in Marrakech.The MENACAB is a treatment advocate network which main aim is to improve...

/ 15 October 2017

ITPC-MENA at the Mediterranean Symposium on HIV and Hepatitis (AFRAMED 2017)

ITPC-MENA at 2nd Mediterranean Symposium on HIV and Hepatitis (AFRAMED 2017) Join ITPC-MENA at AFRAMED 2017 – Hammamet Join ITPC_MENA at 2nd Mediterranean Symposium on HIV and Hepatitis (AFRAMED 2017) in Tunis and Hammamet from 27 – 30 September 2017. We...

/ 21 September 2017

IAS 2017: Closing ceremony exposes Gilead Sciences

Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the closing...

/ 26 July 2017

A new victory for ITPC-MENA : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt

The 9th International AIDS Society Conference on HIV / AIDS 2017 : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt, a victory for ITPC-MENA Today, at the World Conference on AIDS, which is currently taking place in Paris...

/ 25 July 2017

BLOG: We want dolutegravir for all, and we want it now

Source: makemedicinesaffordable Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published on the Huffington Post here. We’re calling for a compulsory license on a ‘new’ HIV drug to be...

/ 25 July 2017